Table 2.
Prevalence of drug resistance among PLWH with virological failure on ART
| TDF + 3TC + NVP/EFV | AZT + 3TC + NVP/EFV | LPV/r + 3TC + AZT/TDF | Others | Total | |
|---|---|---|---|---|---|
| n = 928 (%) | n = 318 (%) | n = 47 (%) | N = 283 (%) | N = 1576 (%) | |
| PIs | 13 (1.40) | 9 (2.83) | 1 (2.13) | 6 (2.12) | 35 (2.22) |
| ATV/r | – | – | – | 1 (0.35) | 2 (0.13) |
| DRV/r | – | – | – | – | – |
| FPV/r | – | 1 (0.31) | – | 1 (0.35) | 3 (0.19) |
| IDV/r | – | – | – | 1 (0.35) | 2 (0.13) |
| LPV/r | – | – | – | 1 (0.35) | 2 (0.13) |
| NFV | 1 (0.11) | 1 (0.31) | – | 2 (0.71) | 6 (0.38) |
| SQV/r | – | – | – | 1 (0.35) | 2 (0.13) |
| TPV/r | 12 (1.29) | 8 (2.52) | 1 (2.13) | 5 (1.77) | 31 (1.97) |
| NRTIs | 97 (10.45) | 55 (17.30) | 2 (4.26) | 39 (13.78) | 232 (14.72) |
| ABC | 92 (9.91) | 55 (17.30) | 2 (4.26) | 39 (13.78) | 227 (14.40) |
| AZT | 26 (2.80) | 22 (6.92) | 2 (4.26) | 8 (2.83) | 66 (4.19) |
| D4T | 44 (4.74) | 26 (8.18) | 2 (4.26) | 19 (6.71) | 110 (6.98) |
| DDI | 45 (4.85) | 25 (7.86) | 2 (4.26) | 19 (6.71) | 110 (6.98) |
| FTC | 91 (9.81) | 55 (17.30) | 2 (4.26) | 39 (13.78) | 226 (14.34) |
| 3TC | 91 (9.81) | 55 (17.30) | 2 (4.26) | 39 (13.78) | 226 (14.34) |
| TDF | 30 (3.23) | 18 (5.66) | 1 (2.13) | 16 (5.65) | 81 (5.14) |
| NNRTIs | 269 (28.99) | 108 (33.96) | 10 (21.28) | 90 (31.80) | 567 (35.98) |
| EFV | 261 (28.13) | 103 (32.39) | 10 (21.28) | 88 (31.10) | 550 (34.90) |
| ETR | 63 (6.79) | 42 (13.21) | 1 (2.13) | 24 (8.48) | 154 (9.77) |
| NVP | 261 (28.13) | 105 (33.02) | 10 (21.28) | 88 (31.10) | 552 (35.03) |
| RPV | 96 (10.34) | 58 (18.24) | 1 (2.13) | 35 (12.37) | 225 (14.28) |
TDF Tenofovir, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, AZT Zidovudine, LPV/r Fosamprenavir/ritonavir, ATV/r Atazanavir/ritonavir, DRv/r Darunavir/ritonavir, FPV/r Fosamprenavir/ritonavir, IDV/r Indinavir/Ritonavir, NFV Nelfinavir, SQV/r Ritonavir-boosted saquinavir, TPV/r Tipranavir/ritonavir, ABC Abacavir, D4T Stavudine, DDI Didanosine, FTC Emtricitabine, ETR Etravirine, RPV Rilpivirine